ISIS 416858 + Placebo
Phase 2Completed 0 watching 0 views this week⚡ Active
49
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
End-stage Renal Disease (ESRD)
Conditions
End-stage Renal Disease (ESRD)
Trial Timeline
Dec 26, 2017 → Jul 10, 2019
NCT ID
NCT03358030About ISIS 416858 + Placebo
ISIS 416858 + Placebo is a phase 2 stage product being developed by Bayer for End-stage Renal Disease (ESRD). The current trial status is completed. This product is registered under clinical trial identifier NCT03358030. Target conditions include End-stage Renal Disease (ESRD).
Hype Score Breakdown
Clinical
17
Activity
12
Company
7
Novelty
5
Community
5
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03358030 | Phase 2 | Completed |
| NCT02553889 | Phase 2 | Completed |
Competing Products
20 competing products in End-stage Renal Disease (ESRD)